A Phase 2 interventional study of RO7490677 and Ruxolitinib in Primary Myelofibrosis, Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis, sponsored by Hoffmann-La Roche. Completed at 23 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-05.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 454 studies in Primary Myelofibrosis with a site in United States — 70 open to participants now, 105 under way, 12 of them phase 3. Primary Myelofibrosis · United States.
Among the 454 studies in Primary Myelofibrosis with a site in United States, this one is the 69th largest by enrollment of the 388 interventional ones that give a count, is one of 11 that started in 2013, is one of 167 in phase 2, and was the 252nd registered.
628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.
Browse Primary Myelofibrosis studies →70 of the 454 studies in Primary Myelofibrosis with a site in United States are open now. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–75 · Healthy volunteers
Damora Therapeutics · Sites in United States, Australia
Ages 18+
University of Utah · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
454 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 167 · Phase 2 220 · Phase 3 45
First in 1992; this study’s year is marked. 11 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is above the median of 43 across 492 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 40 across the 388 interventional studies, 153 across the 35 observational. Of the 328 that completed or were terminated, 152 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 454 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 2 studies filed under Primary Myelofibrosis — fewer than ten, so there is no comparison to draw.
40 of the studies in Primary Myelofibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06479135Phase 3Kartos Therapeutics, Inc.Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | 2026-12-31 |
| NCT06468033Phase 3PharmaEssentiaP1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | 2027-11-18 |
| NCT02934477Center for International Blood and Marrow Transplant ResearchProspective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis | 2026-11 |
| NCT01973881University of Michigan Rogel Cancer CenterQuantitative MRI for Myelofibrosis | 2026-12 |
| NCT06414681University of Kansas Medical CenterCombination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined | 2026-12 |
Add all 40 to your calendar (.ics) → With an account.
Among the 454 studies in Primary Myelofibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
RO7490677 is an investigational drug that is being developed for possible use in the treatment of myelofibrosis (MF), a disease in which the bone marrow, which is the organ in the body that makes blood cells, is replaced by fibrosis, or excess scar tissue.
The purpose of this study is to gather information on whether RO7490677 has an effect on the MF disease, whether it is safe in patients with MF, and how well it is tolerated.
Stage 1 of this study has completed. Stage 1 was an open-label, Simon two stage, Phase 2 study to determine the efficacy and safety of two different dose schedules of RO7490677 in participants with PMF and post ET/PV MF. There were two treatment cohorts, each assigned to one of two dose schedules receiving either single-agent RO7490677 or RO7490677 in combination with ruxolitinib. Participants were assigned to a weekly or every four week dosing schedule by the investigator.
Stage 2 is a randomized, double-blind Phase 2 study to determine the efficacy and safety of three different doses of RO7490677 in participants with PMF and post ET/PV MF. Participants will be randomized to one of three doses: 0.3 mg/kg, 3.0 mg/kg or 10 mg/kg of RO7490677. This is the second stage of an adaptive design study as defined in FDA Draft Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics, February 2010. Modifications to dose levels, schedule, and regimen have been made in Stage 2 based on data from Stage 1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must not be candidates for ruxolitinib based on EITHER:
Must have adequate organ function as demonstrated by the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent RO7490677 at a dose of 10 mg/kg IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.
Biological: RO7490677
Paricipants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent RO7490677 at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.
Biological: RO7490677
Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive RO7490677 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.
Biological: RO7490677 · Drug: Ruxolitinib
Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive RO7490677 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.
Biological: RO7490677 · Drug: Ruxolitinib
Participants will be treated with single agent RO7490677 at a dose of 0.3 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
Biological: RO7490677
Participants will be treated with single agent RO7490677 at a dose of 3.0 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
Biological: RO7490677
Participants will be treated with single agent RO7490677 at a dose of 10 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
Biological: RO7490677
IV infusion
Also known as: originally called PRM-151, and also known as rhPTX-2
IV infusion
Also known as: Jakafi
Stage 1 Main Phase: Overall Response Rate (ORR)
ORR was defined as the percent of participants with a response according to the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria. This was defined as those participants who achieved clinical improvement (CI), partial remission (PR), or complete remission (CR) at a post-baseline assessment of treatment response OR had at least stable disease (SD) for three consecutive end-of-cycle response assessments (e.g. Day 1 of the subsequent cycle) in conjunction with improvement in the bone marrow fibrosis score relative to baseline by at least one grade at any time point during the period of stable disease.
Time frame: Up until and including completion of 6 cycles. Each cycle is 28 days.
Stage 2 Main Phase: Bone Marrow Response Rate (BMRR)
Response rate was defined as the percent of participants with a reduction in bone marrow fibrosis by at least one grade according to World Health Organization (WHO) criteria from baseline to any time during the study. This was determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy.
Time frame: Up until and including completion of 9 cycles. Each cycle is 28 days.
Stage 1 Main + Open-Label Extension (OLE): ORR
ORR was defined as the percent of participants with a response according to the IWG-MRT criteria. This was defined as those participants who achieved CI, PR, or CR at a post-baseline assessment of treatment response OR had at least SD for three consecutive end-of-cycle response assessments (e.g. Day 1 of the subsequent cycle) in conjunction with improvement in the bone marrow fibrosis score relative to baseline by at least one grade at any time point during the period of stable disease. Participants who achieved a clinical benefit in the main phase had the opportunity to remain on treatment. The determination of ORR in the main phase is outlined in the arms description below. Participants who didn't achieve a benefit had the opportunity to switch to a different dosing schedule in the OLE phase. The determination of ORR in the OLE phase is outlined in the arms descriptions below.
Time frame: From cycle 1 day 1 up until cycle 6, day 29 (Main Phase). From cycle 7 day 1 up until study discontinuation or study termination, up to 83 cycles (OLE). Each cycle is 28 days.
Stage 2 Main + Open-Label Extension (OLE): BMRR
Defined as the percent of participants with a reduction in bone marrow fibrosis score by at least one grade according to WHO criteria at any time during the study. As determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy. Participants in the main phase had the opportunity to remain on treatment (as outlined in the arms description below). Participants also had the option to switch to the OLE phase after completing 9 cycles of the originally assigned treatment and receive PRM-151 10 mg/kg/Q4W (as outlined in the arms description below).
Time frame: From cycle 1 day 1 up until cycle 9 day 29 (main phase). From cycle 10 day 1 up until study discontinuation or study termination, up to 51 cycles (OLE). Each cycle is 28 days.
Stage 1 Main Phase: BMRR
Bone marrow response was defined as a reduction in bone marrow fibrosis score by at least one grade from baseline at anytime during the study.
Time frame: Baseline, Weeks 12 and 24
Stage 1 Main Phase: Modified Myeloproliferative Neoplasms Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) Changes
The MPN-SAF TSS total symptom score was the sum of the following 10 items: Filling up quickly when you eat (early satiety), abdominal discomfort, inactivity, Problems with concentration, Worst fatigue, Night sweats, Itching, Bone pain, Fever and Unintentional weight loss last 6 months. The MPN-SAF Total Symptom Score had a possible range of 0 to 100, where a lower score was more favorable. The values reported are the change from baseline scores.
Time frame: Baseline, beginning of each cycle (Cycle 2 onward). Each cycle is 28 days.
Stage 2 Main Phase: BMRR
Response rate was defined as the percent of participants with a reduction in bone marrow fibrosis by at least one grade according to World Health Organization (WHO) criteria at any time during the study. This was determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy.
Time frame: Up until and including completion of 9 cycles. Each cycle is 28 days.
Stage 2 Main Phase: BMRR - Reduction of Bone Marrow Fibrosis by Visit
Reduction in bone marrow fibrosis score: Reduction of at least one grade from baseline. Bone marrow fibrosis grades according to WHO criteria (as determined by central adjudication).
Time frame: Day 1 on Cycles 4, 7, 10 and Cycle 9 Day 29. Each cycle is 28 days.
Stage 2 Main Phase: Duration of Bone Marrow Improvement
Duration of response was defined as time from first decrease from baseline \>= 1 grade to time of return to baseline levels.
Time frame: From first decrease from baseline of one grade to time of return to baseline levels, up to cycle 9 of 28-day cycles.
Stage 2 Main Phase: Hemoglobin Improvement
Hemoglobin improvement was measured by the percent of participants with: Red cell transfusion independence (no transfusions for \>= 12 consecutive weeks) OR 50% reduction in red blood cell (RBC) transfusions for \>= 12 consecutive weeks OR percent of participants with \>= 10 g/L and \>= 20 g/L increase in hemoglobin for \>= 12 consecutive weeks without transfusions (outcome parameter assessed was dependent on baseline hemoglobin/transfusion status).
Time frame: Up until and including completion of 9 cycles. Each cycle is 28 days.
Stage 2 Main Phase: Platelet Improvement
Platelet improvement was measured by the percent of participants with: Platelet transfusion independence (no transfusions for \>= 12 consecutive weeks) OR 50% reduction in platelets transfusions for \>= 12 consecutive weeks OR doubling of baseline platelet count for \>= 12 consecutive weeks without platelet transfusions OR platelet count \> 50 x 10e9/L for \>=12 consecutive weeks without platelet transfusions OR doubling of baseline platelet count for \>= 12 consecutive weeks without platelet transfusions OR platelet count \> 25 x 10e9/L for \>= 12 consecutive weeks without platelet transfusions (outcome parameter assessed is dependent on baseline platelet status).
Time frame: Up until and including completion of 9 cycles. Each cycle is 28 days.
Stage 2 Main Phase: Symptom Improvement
Symptom improvement was assessed as the percent of participants with 50% reduction in MPN-SAF TSS from baseline over time. The MPN-SAF TSS total symptom score was the sum of the following 10 items: Filling up quickly when you eat (early satiety), abdominal discomfort, inactivity, Problems with concentration, Worst fatigue, Night sweats, Itching, Bone pain, Fever and Unintentional weight loss last 6 months. The MPN-SAF Total Symptom Score had a possible range of 0 to 100, where a lower score was more favorable.
Time frame: Up until and including completion of 9 cycles. Each cycle is 28 days.
Stage 2 Main Phase: Percentage of Participants With Complete Response (CR), Partial Response (PR), Clinical Improvement (CI), Stable Disease (SD), and Progressive Disease (PD) According to IWG-MRT Criteria
Best Overall Response: (CR, PR, CI), SD and PD according to the IWG-MRT Criteria.
Time frame: Up until and including completion of 9 cycles. Each cycle is 28 days.
Stage 1 Main Phase: Maximum Drug Concentration (Cmax)
Cmax is the maximum observed RO7490677 plasma concentration.
Time frame: Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Stage 1 Main Phase: Time to Maximum Concentration (Tmax)
Time at which the maximum plasma concentration was observed.
Time frame: Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Stage 1 Main Phase: Area Under the Curve up to the Last Measurable Concentration (AUC0-last)
Area under the plasma concentration time curve from time 0 to time of last measurable plasma concentration.
Time frame: Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Stage 1 Main Phase: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf)
Area under the plasma concentration-time curve from 0-time extrapolated to infinity.
Time frame: Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Stage 1 Main Phase: Terminal Elimination Half-Life (T1/2)
Apparent terminal elimination half-life of RO7490677.
Time frame: Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Stage 1 Main Phase: Clearance (CL)
Time frame: Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Stage 1 Main Phase: Volume of Distribution (Vd)
Time frame: Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Percentage of Participants With Adverse Events (AEs) and Infusion Related Reactions (IRRs)
An AE was defined as any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered investigational product-related. Pre-existing conditions which worsened during the study were also considered as adverse events. IRRs were considerd to be Adverse Events of Special Interest (AESI). Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0.
Time frame: Baseline up until 6.75 years
Percentage of Participants With Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation
An SAE was defined as any AE that occurred at any dose the resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalizations; a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; a congenital anomaly or birth defect. An AE was defined as any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered investigational product-related. Pre-existing conditions which worsened during the study were also considered as adverse events. Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0.
Time frame: Baseline up until 6.75 years
A total of 125 participants were enrolled at sites in 8 different countries.
| Milestone | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W | OLE Stage 1: RO7490677 10 mg/kg IV Q4W | OLE Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib | OLE Stage 2: RO7490677 10 mg/kg IV Q4W |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 8 | 7 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 5 | 5 | 4 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Informed consent withdrawn | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Various reasons | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W | OLE Stage 1: RO7490677 10 mg/kg IV Q4W | OLE Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib | OLE Stage 2: RO7490677 10 mg/kg IV Q4W |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 33 | 32 | 32 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 20 | 16 | 15 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 13 | 16 | 17 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 6 | 5 | 7 | 0 | 0 | 0 |
| Withdrew: Informed consent withdrawn | 0 | 0 | 0 | 0 | 4 | 3 | 3 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Various reasons | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 0 | 0 | 0 |
| Milestone | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W | OLE Stage 1: RO7490677 10 mg/kg IV Q4W | OLE Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib | OLE Stage 2: RO7490677 10 mg/kg IV Q4W |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 5 | 48 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 5 | 48 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 8 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 19 |
| Withdrew: Various reasons | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 3 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 9 |
| Withdrew: Informed consent withdrawn | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
ORR was defined as the percent of participants with a response according to the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria. This was defined as those participants who achieved clinical improvement (CI), partial remission (PR), or complete remission (CR) at a post-baseline assessment of treatment response OR had at least stable disease (SD) for three consecutive end-of-cycle response assessments (e.g. Day 1 of the subsequent cycle) in conjunction with improvement in the bone marrow fibrosis score relative to baseline by at least one grade at any time point during the period of stable disease.
| Percentage of Participants | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib |
|---|---|---|---|---|
| Stage 1 Main Phase: Overall Response Rate (ORR) | 37.5 (11.11 to 71.08) | 14.3 (0.73 to 52.07) | 33.3 (6.28 to 72.87) | 50.0 (15.32 to 84.68) |
Response rate was defined as the percent of participants with a reduction in bone marrow fibrosis by at least one grade according to World Health Organization (WHO) criteria from baseline to any time during the study. This was determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy.
| Percentage of Participants | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W |
|---|---|---|---|
| Stage 2 Main Phase: Bone Marrow Response Rate (BMRR) | 30.3 (14.62 to 45.98) | 31.3 (15.19 to 47.31) | 25.0 (10.00 to 40.00) |
ORR was defined as the percent of participants with a response according to the IWG-MRT criteria. This was defined as those participants who achieved CI, PR, or CR at a post-baseline assessment of treatment response OR had at least SD for three consecutive end-of-cycle response assessments (e.g. Day 1 of the subsequent cycle) in conjunction with improvement in the bone marrow fibrosis score relative to baseline by at least one grade at any time point during the period of stable disease. Participants who achieved a clinical benefit in the main phase had the opportunity to remain on treatment. The determination of ORR in the main phase is outlined in the arms description below. Participants who didn't achieve a benefit had the opportunity to switch to a different dosing schedule in the OLE phase. The determination of ORR in the OLE phase is outlined in the arms descriptions below.
| Percentage of Participants | Main Phase Stage 1: RO7490677 10 mg/kg IV QW; OLE: RO7490677 10 mg/kg IV Q4W | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W; OLE: RO7490677 10 mg/kg IV Q4W | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib; OLE: RO7490677 10 mg/kg IV Q4W + Ruxo. | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib; OLE: RO7490677 10 mg/kg IV Q4W + Ruxo. |
|---|---|---|---|---|
| Stage 1 Main + Open-Label Extension (OLE): ORR | 50.0 (19.29 to 80.71) | 71.4 (34.13 to 94.66) | 50.0 (15.32 to 84.68) | 66.7 (27.13 to 93.72) |
Defined as the percent of participants with a reduction in bone marrow fibrosis score by at least one grade according to WHO criteria at any time during the study. As determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy. Participants in the main phase had the opportunity to remain on treatment (as outlined in the arms description below). Participants also had the option to switch to the OLE phase after completing 9 cycles of the originally assigned treatment and receive PRM-151 10 mg/kg/Q4W (as outlined in the arms description below).
| Percentage of Participants | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W; OLE: RO7490677 10 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W; OLE: RO7490677 10 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W; OLE: RO7490677 10 mg/kg IV Q4W |
|---|---|---|---|
| Stage 2 Main + Open-Label Extension (OLE): BMRR | 30.3 (14.62 to 45.98) | 34.4 (17.92 to 50.83) | 25.0 (10.00 to 40.00) |
Bone marrow response was defined as a reduction in bone marrow fibrosis score by at least one grade from baseline at anytime during the study.
| Percentage of Participants | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib |
|---|---|---|---|---|
| Stage 1 Main Phase: BMRR | 37.5 (3.95 to 71.05) | 14.3 (0.00 to 40.21) | 16.7 (0.00 to 46.49) | 50.0 (9.99 to 90.01) |
The MPN-SAF TSS total symptom score was the sum of the following 10 items: Filling up quickly when you eat (early satiety), abdominal discomfort, inactivity, Problems with concentration, Worst fatigue, Night sweats, Itching, Bone pain, Fever and Unintentional weight loss last 6 months. The MPN-SAF Total Symptom Score had a possible range of 0 to 100, where a lower score was more favorable. The values reported are the change from baseline scores.
| Score on a scale | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib |
|---|---|---|---|---|
| Baseline | 23.1 ± 19.1 | 16.9 ± 7.2 | 26.8 ± 17.1 | 15.3 ± 10.4 |
| Cycle(C)2 Day(D)1 | -5.3 ± 12.6 | 5.7 ± 11.8 | 0.5 ± 8.8 | -2.0 ± 5.0 |
| C3D1 | -9.1 ± 10.9 | 1.9 ± 5.3 | -2.7 ± 14.8 | 4.2 ± 8.0 |
| C4D1 | -8.7 ± 10.7 | 1.0 ± 8.0 | -7.5 ± 6.0 | 5.7 ± 20.9 |
| C5D1 | -13.2 ± 13.2 | 2.6 ± 6.9 | -6.7 ± 10.6 | 1.5 ± 13.6 |
| C6D1 | -12.2 ± 9.5 | -0.8 ± 8.3 | -5.4 ± 6.2 | 4.3 ± 11.5 |
| C6D29 | -15.0 ± 13.7 | -2.2 ± 5.3 | -5.3 ± 4.6 | 2.3 ± 8.8 |
Response rate was defined as the percent of participants with a reduction in bone marrow fibrosis by at least one grade according to World Health Organization (WHO) criteria at any time during the study. This was determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy.
| Percentage of Participants | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W |
|---|---|---|---|
| Stage 2 Main Phase: BMRR | 30.3 (14.62 to 45.98) | 31.3 (15.19 to 47.31) | 25.0 (10.0 to 40.00) |
Reduction in bone marrow fibrosis score: Reduction of at least one grade from baseline. Bone marrow fibrosis grades according to WHO criteria (as determined by central adjudication).
| Percentage of Participants | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W |
|---|---|---|---|
| Cycle(C) 4 Day(D) 1 | 10.7 | 24.0 | 19.2 |
| C7D1 | 23.8 | 11.8 | 10.5 |
| C9D29/C10D1 | 30.0 | 21.4 | 13.3 |
Duration of response was defined as time from first decrease from baseline \>= 1 grade to time of return to baseline levels.
| Weeks | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W |
|---|---|---|---|
| Stage 2 Main Phase: Duration of Bone Marrow Improvement | NA (12.0 to NA) | 12.0 (12.0 to NA) | 12.1 (11.4 to 13.0) |
Hemoglobin improvement was measured by the percent of participants with: Red cell transfusion independence (no transfusions for \>= 12 consecutive weeks) OR 50% reduction in red blood cell (RBC) transfusions for \>= 12 consecutive weeks OR percent of participants with \>= 10 g/L and \>= 20 g/L increase in hemoglobin for \>= 12 consecutive weeks without transfusions (outcome parameter assessed was dependent on baseline hemoglobin/transfusion status).
| Percentage of Participants | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W |
|---|---|---|---|
| Stage 2 Main Phase: Hemoglobin Improvement | 15.2 | 15.6 | 6.3 |
Platelet improvement was measured by the percent of participants with: Platelet transfusion independence (no transfusions for \>= 12 consecutive weeks) OR 50% reduction in platelets transfusions for \>= 12 consecutive weeks OR doubling of baseline platelet count for \>= 12 consecutive weeks without platelet transfusions OR platelet count \> 50 x 10e9/L for \>=12 consecutive weeks without platelet transfusions OR doubling of baseline platelet count for \>= 12 consecutive weeks without platelet transfusions OR platelet count \> 25 x 10e9/L for \>= 12 consecutive weeks without platelet transfusions (outcome parameter assessed is dependent on baseline platelet status).
| Percentage of Participants | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W |
|---|---|---|---|
| Stage 2 Main Phase: Platelet Improvement | 27.3 | 34.4 | 37.5 |
Symptom improvement was assessed as the percent of participants with 50% reduction in MPN-SAF TSS from baseline over time. The MPN-SAF TSS total symptom score was the sum of the following 10 items: Filling up quickly when you eat (early satiety), abdominal discomfort, inactivity, Problems with concentration, Worst fatigue, Night sweats, Itching, Bone pain, Fever and Unintentional weight loss last 6 months. The MPN-SAF Total Symptom Score had a possible range of 0 to 100, where a lower score was more favorable.
| Participants | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W |
|---|---|---|---|
| Cycle(C) 2 Day(D) 1 | 5 | 2 | 1 |
| C3D1 | 6 | 3 | 2 |
| C4D1 | 3 | 4 | 2 |
| C5D1 | 5 | 2 | 1 |
| C6D1 | 8 | 3 | 3 |
| C7D1 | 8 | 5 | 0 |
| C8D1 | 5 | 3 | 0 |
| C9D1 | 5 | 3 | 1 |
| C9D29/C10D1 | 5 | 2 | 0 |
Best Overall Response: (CR, PR, CI), SD and PD according to the IWG-MRT Criteria.
| Participants | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W |
|---|---|---|---|
| CR | 0 | 0 | 0 |
| PR | 0 | 0 | 0 |
| CI | 8 | 6 | 2 |
| SD | 20 | 21 | 26 |
| PD | 3 | 3 | 4 |
| Not evaluable | 2 | 2 | 0 |
Cmax is the maximum observed RO7490677 plasma concentration.
| Micrograms per Milliliter (ug/mL) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib |
|---|---|---|---|---|
| C1D1 | 133 ± 48.4 | 113 ± 28.1 | 164 ± 23.9 | 112 ± 90.4 |
| C1D15 | 127 ± 31.9 | — | 126 ± 27.5 | — |
| C2D1 | 107 ± 26.9 | 110 ± 20.9 | 149 ± 29.1 | 130 ± 80.2 |
| C6D1 | 142 ± 70.0 | 111 ± 28.0 | 136 ± 34.1 | 142 ± 27.4 |
Time at which the maximum plasma concentration was observed.
| Hour (hr) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib |
|---|---|---|---|---|
| C1D1 | 1.12 (1.00 to 2.00) | 1.10 (1.00 to 2.08) | 1.14 (1.00 to 2.25) | 1.13 (1.00 to 5.00) |
| C1D15 | 1.13 (1.03 to 1.80) | — | 1.65 (1.02 to 2.50) | — |
| C2D1 | 1.10 (1.00 to 3.17) | 1.08 (1.03 to 1.08) | 1.05 (1.00 to 1.32) | 1.44 (1.00 to 9.00) |
| C6D1 | 2.00 (1.03 to 5.20) | 1.07 (1.00 to 2.03) | 1.17 (1.05 to 5.00) | 1.01 (1.00 to 1.08) |
Area under the plasma concentration time curve from time 0 to time of last measurable plasma concentration.
| ug*hour/mL | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib |
|---|---|---|---|---|
| C1D1 | 1810 ± 72.0 | 1690 ± 26.1 | 2590 ± 28.7 | 1500 ± 158.3 |
| C1D15 | 1460 ± 142.0 | — | 2590 ± 187.6 | — |
| C2D1 | 127.3 ± 904 | 504 ± 84.7 | 2990 ± 92.0 | 663 ± 79.5 |
| C6D1 | 698 ± 63.0 | 570 ± 44.8 | 764 ± 28.9 | 703 ± 33.8 |
Area under the plasma concentration-time curve from 0-time extrapolated to infinity.
| ug*hour/mL | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib |
|---|---|---|---|---|
| C1D1 | 2830 ± 12.9 | 2050 ± 29.5 | 2970 ± 34.9 | 3130 ± 8.6 |
| C1D15 | 3450 ± 2.8 | — | 6060 ± 23.2 | — |
| C2D1 | 2170 ± 170.9 | — | 4230 ± 34.8 | — |
| C6D1 | — | — | 819 ± NA | — |
Apparent terminal elimination half-life of RO7490677.
| hr | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib |
|---|---|---|---|---|
| C1D1 | 14.7 ± 19.2 | 17.2 ± 23.7 | 16.8 ± 17.7 | 18.4 ± 7.9 |
| C1D15 | 31.2 ± 45.0 | — | 40.4 ± 12.6 | — |
| C2D1 | 18.0 ± 220.6 | — | 30.0 ± 48.6 | — |
| C6D1 | — | — | 1.95 ± NA | — |
| Litres per hour (L/hr) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib |
|---|---|---|---|---|
| C1D1 | 0.258 ± 9.0 | 0.362 ± 31.5 | 0.269 ± 32.9 | 0.233 ± 33.3 |
| C1D15 | 0.233 ± 24.9 | — | 0.147 ± 35.0 | — |
| C2D1 | 0.382 ± 229.9 | — | 0.189 ± 55.5 | — |
| C6D1 | — | — | 1.42 ± NA | — |
| Litres (L) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib |
|---|---|---|---|---|
| C1D1 | 5.47 ± 10.9 | 9.00 ± 28.8 | 6.52 ± 26.4 | 6.17 ± 38.9 |
| C1D15 | 10.5 ± 62.4 | — | 8.57 ± 47.6 | — |
| C2D1 | 9.93 ± 63.0 | — | 8.18 ± 24.5 | — |
| C6D1 | — | — | 4.01 ± NA | — |
An AE was defined as any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered investigational product-related. Pre-existing conditions which worsened during the study were also considered as adverse events. IRRs were considerd to be Adverse Events of Special Interest (AESI). Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0.
| Percentage of Participants | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W | OLE Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | OLE Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | OLE Stage 2: RO7490677 10 mg/kg IV Q4W |
|---|---|---|---|---|---|---|---|---|---|---|
| AEs | 100 | 85.7 | 100 | 100 | 100 | 100 | 100 | 92.3 | 100 | 89.6 |
| IRRs | 0 | 0 | 0 | 16.7 | 3.0 | 3.1 | 6.3 | 7.7 | 20.0 | 2.1 |
An SAE was defined as any AE that occurred at any dose the resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalizations; a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; a congenital anomaly or birth defect. An AE was defined as any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered investigational product-related. Pre-existing conditions which worsened during the study were also considered as adverse events. Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0.
| Percentage of Participants | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W | OLE Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | OLE Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | OLE Stage 2: RO7490677 10 mg/kg IV Q4W |
|---|---|---|---|---|---|---|---|---|---|---|
| SAEs | 25.0 | 0 | 0 | 0 | 15.2 | 15.6 | 28.1 | 7.7 | 0 | 22.9 |
| AEs | 25.0 | 0 | 0 | 0 | 21.2 | 34.4 | 37.5 | 30.8 | 0 | 27.1 |
Collected over Baseline up until 6.75 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | 2/8 (25%) | 2/8 (25%) | 8/8 (100%) |
| Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | 0/7 (0%) | 1/7 (14.3%) | 6/7 (85.7%) |
| Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | 1/6 (16.7%) | 2/6 (33.3%) | 6/6 (100%) |
| Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | 7/33 (21.2%) | 11/33 (33.3%) | 32/33 (97%) |
| Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | 6/32 (18.8%) | 14/32 (43.8%) | 30/32 (93.8%) |
| Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W | 9/32 (28.1%) | 14/32 (43.8%) | 31/32 (96.9%) |
| OLE Stage 1: RO7490677 10 mg/kg IV Q4W | 0/13 (0%) | 5/13 (38.5%) | 12/13 (92.3%) |
| OLE Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| OLE Stage 2: RO7490677 10 mg/kg IV Q4W | 7/48 (14.6%) | 22/48 (45.8%) | 32/48 (66.7%) |
| Event | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W | OLE Stage 1: RO7490677 10 mg/kg IV Q4W | OLE Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib | OLE Stage 2: RO7490677 10 mg/kg IV Q4W |
|---|---|---|---|---|---|---|---|---|---|---|
| InfectionInfections and infestations | 0/8 | 0/7 | 0/6 | 0/6 | 0/33 | 0/32 | 0/32 | 0/13 | 1/5 | 1/48 |
| PneumoniaInfections and infestations | 0/8 | 0/7 | 1/6 | 0/6 | 2/33 | 1/32 | 2/32 | 0/13 | 1/5 | 3/48 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/8 | 0/7 | 0/6 | 0/6 | 0/33 | 0/32 | 0/32 | 0/13 | 1/5 | 0/48 |
| Enterocolitis infectiousInfections and infestations | 0/8 | 0/7 | 0/6 | 0/6 | 0/33 | 0/32 | 0/32 | 0/13 | 1/5 | 0/48 |
| Wound infectionInfections and infestations | 0/8 | 0/7 | 0/6 | 0/6 | 0/33 | 0/32 | 0/32 | 1/13 | 1/5 | 0/48 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/8 | 0/7 | 0/6 | 0/6 | 0/33 | 0/32 | 0/32 | 0/13 | 1/5 | 0/48 |
| Respiratory syncytial virus infectionInfections and infestations | 0/8 | 0/7 | 1/6 | 0/6 | 0/33 | 0/32 | 0/32 | 0/13 | 0/5 | 0/48 |
| SialoadenitisInfections and infestations | 0/8 | 0/7 | 1/6 | 0/6 | 0/33 | 0/32 | 0/32 | 0/13 | 0/5 | 0/48 |
| Abdominal painGastrointestinal disorders | 0/8 | 1/7 | 0/6 | 0/6 | 0/33 | 0/32 | 1/32 | 0/13 | 0/5 | 0/48 |
| Cardiac arrestCardiac disorders | 1/8 | 0/7 | 0/6 | 0/6 | 0/33 | 0/32 | 0/32 | 0/13 | 0/5 | 0/48 |
| Event | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W | OLE Stage 1: RO7490677 10 mg/kg IV Q4W | OLE Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib | OLE Stage 2: RO7490677 10 mg/kg IV Q4W |
|---|---|---|---|---|---|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/8 | 0/7 | 1/6 | 1/6 | 3/33 | 5/32 | 2/32 | 2/13 | 4/5 | 3/48 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/8 | 0/7 | 0/6 | 0/6 | 2/33 | 0/32 | 0/32 | 0/13 | 3/5 | 0/48 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/8 | 0/7 | 2/6 | 1/6 | 10/33 | 7/32 | 5/32 | 2/13 | 3/5 | 4/48 |
| PyrexiaGeneral disorders | 0/8 | 0/7 | 0/6 | 3/6 | 4/33 | 7/32 | 3/32 | 0/13 | 1/5 | 2/48 |
| NauseaGastrointestinal disorders | 2/8 | 1/7 | 1/6 | 0/6 | 2/33 | 2/32 | 5/32 | 4/13 | 2/5 | 3/48 |
| VomitingGastrointestinal disorders | 0/8 | 1/7 | 1/6 | 0/6 | 1/33 | 2/32 | 5/32 | 2/13 | 2/5 | 0/48 |
| BronchitisInfections and infestations | 0/8 | 0/7 | 0/6 | 0/6 | 3/33 | 0/32 | 1/32 | 0/13 | 2/5 | 0/48 |
| Alanine aminotransferase increasedInvestigations | 3/8 | 0/7 | 0/6 | 0/6 | 2/33 | 4/32 | 1/32 | 0/13 | 2/5 | 0/48 |
| Aspartate aminotransferase increasedInvestigations | 0/8 | 0/7 | 0/6 | 0/6 | 1/33 | 5/32 | 1/32 | 0/13 | 2/5 | 0/48 |
| HeadacheNervous system disorders | 0/8 | 0/7 | 2/6 | 1/6 | 4/33 | 7/32 | 3/32 | 2/13 | 2/5 | 3/48 |
Stage 1 \& Stage 2 reported separately.
| Age, Continuous(Years) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 64.3 ± 11.4 | 70.7 ± 6.3 | 66.0 ± 7.3 | 66.2 ± 8.6 | — | — | — | 66.7 ± 8.7 |
| Age, Continuous(Years) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | — | — | — | — | 70.6 ± 7.1 | 70.2 ± 6.5 | 69.4 ± 8.9 | 70.1 ± 7.5 |
| Sex: Female, Male(Participants) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 5 | 2 | 3 | 5 | — | — | — | 15 |
| Male | 3 | 5 | 3 | 1 | — | — | — | 12 |
| Sex: Female, Male(Participants) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W | Total |
|---|---|---|---|---|---|---|---|---|
| Female | — | — | — | — | 16 | 8 | 11 | 35 |
| Male | — | — | — | — | 17 | 24 | 21 | 62 |
| Ethnicity (NIH/OMB)(Participants) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | — | — | — | 1 |
| Not Hispanic or Latino | 8 | 7 | 4 | 6 | — | — | — | 25 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | — | — | — | 1 |
| Race (NIH/OMB)(Participants) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | — | — | — | 1 |
| Asian | 0 | 0 | 1 | 0 | — | — | — | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | — | — | — | 0 |
| Black or African American | 1 | 0 | 1 | 0 | — | — | — | 2 |
| White | 7 | 7 | 3 | 6 | — | — | — | 23 |
| More than one race | 0 | 0 | 0 | 0 | — | — | — | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | — | — | — | 0 |
| Race (NIH/OMB)(Participants) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW) | Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W) | Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib | Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib | Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W | Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | — | — | — | — | 0 | 0 | 0 | 0 |
| Asian | — | — | — | — | 0 | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | — | — | — | — | 0 | 0 | 0 | 0 |
| Black or African American | — | — | — | — | 0 | 1 | 0 | 1 |
| White | — | — | — | — | 33 | 29 | 29 | 91 |
| More than one race | — | — | — | — | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | — | — | — | — | 0 | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Oct 2013 to primary completion in Jul 2020, 81 months.
Results were first posted in Jan 2022, 1 year 5 months after primary completion.
Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's 81 months is above that.
Counting every sponsor, half of 97 studies reached it within 66 months; a quarter within 32 and three quarters within 111.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PRM-151